CCT5

Across TCGA pan-cancer cohorts, CCT5 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CCT5 data layer compared with 5 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CCT5 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CCT5 expression acts as an unfavorable survival marker, although some lineages such as READ and GBM show a favorable association.

MESO, LIHC, and UVM are the cancer types where CCT5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.411	0.684	<.001	124	view →
LIHC	OS	Median	All	0.609	0.758	<.001	111	view →
UVM	DFS	Median	All	0.414	0.776	<.001	97	view →
KIRP	DFS	Median	All	0.854	0.957	<.001	88	view →
ACC	OS	Tertile	All	0.729	0.974	<.001	68	view →
PAAD	OS	Median	All	0.517	0.749	.005	48	view →
SARC	OS	Tertile	All	0.408	0.636	<.001	43	view →
LUAD	DFS	Median	All	0.741	0.838	.002	39	view →
BRCA	OS	Tertile	II,III,IV	0.874	0.942	<.001	36	view →
COAD	DFS	Tertile	III,IV	0.228	0.735	.001	33	view →
READ	OS	Median	All	0.966	0.440	.006	29	view →
BLCA	DFS	Median	III,IV	0.381	0.579	.017	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CCT5–MESO (OS)

Open the MESO breakdown →